Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280140 | 1.00 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL1280479 | 0.82 | SLC6A2 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1280894 | 0.82 | SLC6A2 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1280478 | 0.82 | SLC6A2 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL15693953 | 0.82 | NPC1 (0.37) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL1692463 | 0.82 | NPC1 (0.37) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL15307502 | 0.82 | NPC1 (0.37) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL1281490 | 0.74 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1280233 | 0.74 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1280231 | 0.74 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | MAOB, SLC6A4, SLC6A2 | SLC6A3 6/4885SLC6A2 3/4885SLC6A4 2/4885 |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | SLC6A3 4/4885SLC6A2 1/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.